<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01713218</url>
  </required_header>
  <id_info>
    <org_study_id>2012-003516-31</org_study_id>
    <nct_id>NCT01713218</nct_id>
  </id_info>
  <brief_title>Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer</brief_title>
  <acronym>NEOPACHI-001</acronym>
  <official_title>Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Neoadjuvant Chemotherapy Combining Gemcitabine and a Hedgehog Inhibitor (Vismodegib) in Patients With Resectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jean-Luc Van Laethem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses of all human cancers&#xD;
      and is considered as a sanctuary, resistant to most of the drugs used. Identification of new&#xD;
      molecular targets involved in its pathogenesis is urgently needed and required both proper&#xD;
      and innovative efficacy assessment.&#xD;
&#xD;
      This proof-of-concept trial is studying the &quot;dynamic&quot; tumor response after the administration&#xD;
      of a short course (4 weeks) neoadjuvant combination of gemcitabine and a Hedgehog inhibitor&#xD;
      (Vismodegib) before surgery in patients with operable pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is characterized by a high stromal density and is a hypoperfused tumor,&#xD;
      precluding cytotoxics delivery to the epithelial tumoral compartment. There is thus a&#xD;
      rationale for combining chemotherapy and antistromal drugs like Hedgehog inhibitors.&#xD;
      Targeting the resectable primary tumor offers an appropriate setting to (1) evaluate and&#xD;
      monitor early treatment effects on the tumor, (2) correlate dynamic imaging changes&#xD;
      (perfusion and diffusion coefficient) to pre- and post-therapeutic tissue changes, (3)&#xD;
      identify specific predictive biomarkers for the drugs used (i.e. gemcitabine transporters and&#xD;
      Hedgehog pathway genes and proteins) and (4) assess if this early &quot;dynamic and biomolecular&#xD;
      response&quot; can predict treatment benefit and patient outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Dynamic&quot; tumor response rate as defined by a 20% modification of tumoral perfusion and cellular density parameters.</measure>
    <time_frame>4 weeks (duration of the neoadjuvant chemotherapy).</time_frame>
    <description>In order to detect changes in the tumor microenvironment and to monitor treatment efficacy, Dynamic Contrast-Enhanced-Magnetic Resonance Imaging (DCE-MRI) and Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) constitute tools more and more used. The acquired data can be analyzed using a pharmacokinetic model to obtain quantitative parameters relative to tissue perfusion and vascular permeability (Ktrans, a volume transfer constant of contrast agent between blood plasma and the extravascular extracellular space; Apparent Diffusion Coefficient as a surrogate marker of tissue cellularity). DCE/DW-MRI will be achieved weekly before each neoadjuvant chemotherapy treatment and before surgery. Each patient will be his/her own control by comparing serial imaging results with those of the baseline MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as assessed by National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0.</measure>
    <time_frame>End of study follow-up (up to 2 years).</time_frame>
    <description>Number of participants with (serious) adverse events will be considered as a measure of safety of the whole therapeutic sequence (gemcitabine + Hedgehog inhibitor+ surgery).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.</measure>
    <time_frame>4 weeks (duration of the neoadjuvant chemotherapy).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect of treatment on selected biomarkers in tumor resection specimens.</measure>
    <time_frame>4 weeks (duration of the neoadjuvant chemotherapy).</time_frame>
    <description>The objective is to identify within pre-therapeutic samples and surgical specimens several specific biomarkers involved (1) in the Hedgehog signalling pathway (GLI1, Sonic Hedgehog, Patched, Smoothened immunohistochemical patterns protein expression) and predicting response to anti-Hh therapy, (2) in the metabolization of gemcitabine (human equilibrative nucleoside transporter 1, deoxycytidine kinase) and predicting response to gemcitabine therapy, and (3) in the relative contribution of both anti-Hh therapy and gemcitabine therapy.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Pancreatic Adenocarcinoma Resectable</condition>
  <arm_group>
    <arm_group_label>Gemcitabine+Vismodegib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4</description>
    <arm_group_label>Gemcitabine+Vismodegib</arm_group_label>
    <other_name>GEMZAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>150 mg capsule, oral, once daily</description>
    <arm_group_label>Gemcitabine+Vismodegib</arm_group_label>
    <other_name>GDC-0449</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy</intervention_name>
    <description>Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery</description>
    <arm_group_label>Gemcitabine+Vismodegib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histo(cyto)logically proven ductal pancreatic adenocarcinoma&#xD;
&#xD;
          -  Resectable or potentially resectable tumor; resectability assessed during a&#xD;
             multidisciplinary meeting with expert surgeon and radiologist&#xD;
&#xD;
          -  First line chemotherapy&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  WHO performance status (PS) grade 0 or 1;&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1.5 x 10 9 / L, platelets &gt; 100 x 10 9/ L, creatinine&#xD;
             clearance (Cockcroft and Gault formula) &gt; 60 ml/min, haemoglobin level &gt; 10 g/dl&#xD;
             (transfusions authorized), bilirubin&lt;1.5 g/dl;&#xD;
&#xD;
          -  Optimal biliary drainage;&#xD;
&#xD;
          -  Women of child-bearing potential (WCBP), defined as a sexually mature woman who has&#xD;
             not undergone a hysterectomy or tubal ligation of who has not been naturally&#xD;
             postmenopausal for at least 24 consecutive months, must have a negative serum or urine&#xD;
             pregnancy test prior to treatment. All WCBP, all sexually active male patients, and&#xD;
             all partners of patients must agree to use adequate methods of birth control&#xD;
             throughout the study;&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Locally advanced non resectable or metastatic pancreatic adenocarcinoma&#xD;
&#xD;
          -  Previous anticancer therapy for the pancreatic adenocarcinoma&#xD;
&#xD;
          -  Biliary obstruction without endoscopic biliary drainage&#xD;
&#xD;
          -  Any contre-indication for surgery&#xD;
&#xD;
          -  Prior malignancy (except non-melanoma skin cancer, and in situ carcinoma of the&#xD;
             uterine cervix treated with a curative intent and any other tumor in complete&#xD;
             remission with a disease-free interval &gt; 3 years)&#xD;
&#xD;
          -  Uncontrolled congestive heart failure or angina pectoris, myocardial infarction within&#xD;
             1 year prior to study entry, uncontrolled hypertension (systolic pressure &gt; 160 mm or&#xD;
             diastolic pressure &gt; 100 mm under well conducted antihypertensive treatment), QT&#xD;
             prolongation&#xD;
&#xD;
          -  Major uncontrolled infection&#xD;
&#xD;
          -  Severe hepatic impairment&#xD;
&#xD;
          -  Any medical, psychological, or social condition, which, in the opinion of the&#xD;
             investigator, could hamper patient's compliance to the study protocol and/or&#xD;
             assessment/interpretation of the data&#xD;
&#xD;
          -  Pregnant or lactating women, or patients of both genders with procreative potential&#xD;
             not using adequate contraceptive methods&#xD;
&#xD;
          -  Patients receiving or having received any investigational treatment within 4 weeks&#xD;
             prior to study entry, or participating to another clinical study;Subject previously&#xD;
             enrolled into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc Van Laethem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Luc Van Laethem, MD, PhD</last_name>
    <email>jl.vanlaethem@erasme.ulb.ac.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Antwerp University Hospital (UZA)</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Peeters, MD,PhD</last_name>
      <email>marc.peeters@uza.be</email>
    </contact>
    <investigator>
      <last_name>Marc Peeters, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasme University Hospital (ULB)</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Luc Van Laethem, MD, PhD</last_name>
      <email>jl.vanlaethem@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc Van Laethem, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël Maréchal, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Demols, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 17, 2012</study_first_submitted>
  <study_first_submitted_qc>October 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>October 22, 2012</last_update_submitted>
  <last_update_submitted_qc>October 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Jean-Luc Van Laethem</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>Cancer</keyword>
  <keyword>Hedgehog inhibitor</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Dynamic imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

